Short answer · Medically reviewed summary · Last updated: 2026-05-08
TL;DR: 1p36 Deletion Syndrome is currently managed through supportive therapies rather than curative treatments, though research is shifting toward understanding the specific gene-dosage effects of the terminal 1p36 deletion. While no gene therapy is yet available, recent studies are utilizing advanced genomic profiling to better correlate specific deleted regions with clinical outcomes, paving the way for future precision medicine interventions. What is the current focus of 1p36 Deletion Syndrome research? Modern research into 1p36 Deletion Syndrome is increasingly focused on genotype-phenotype correlations.
What are the latest advances in 1p36 Deletion Syndrome?
Latest advances in 1p36 Deletion Syndrome: recent research, treatments in development and what they could mean, with sources.
TL;DR: 1p36 Deletion Syndrome is currently managed through supportive therapies rather than curative treatments, though research is shifting toward understanding the specific gene-dosage effects of the terminal 1p36 deletion. While no gene therapy is yet available, recent studies are utilizing advanced genomic profiling to better correlate specific deleted regions with clinical outcomes, paving the way for future precision medicine interventions.
What is the current focus of 1p36 Deletion Syndrome research?
Modern research into 1p36 Deletion Syndrome is increasingly focused on genotype-phenotype correlations. Because the deletion size varies significantly among patients, researchers are using high-resolution chromosomal microarrays to identify which specific genes—such as PRDM16 or KCNAB2—contribute most significantly to features like cardiomyopathy and epilepsy. By mapping these specific gene losses, clinicians hope to develop targeted management strategies for 1p36 Deletion Syndrome.
Are there active clinical trials for 1p36 Deletion Syndrome?
Currently, there are no curative clinical trials specifically for 1p36 Deletion Syndrome. Most clinical research centers on registry studies that track the natural history of the condition. These longitudinal studies are vital for establishing a baseline that will eventually allow for the evaluation of future therapeutic interventions. Current research priorities include:
- Natural history studies to document developmental milestones in children with 1p36 Deletion Syndrome.
- Advanced neuroimaging research to understand the structural brain differences associated with the syndrome.
- Pharmacological studies aimed at better managing the refractory epilepsy often seen in 1p36 Deletion Syndrome patients.
How can patients contribute to 1p36 Deletion Syndrome research?
Patient participation is the primary driver of progress for rare conditions like 1p36 Deletion Syndrome. Engaging with global consortia and registries allows researchers to aggregate the data necessary for breakthroughs. Our DiseaseMaps.org community currently includes 22 individuals living with 1p36 Deletion Syndrome, whose shared experiences are invaluable for identifying common clinical challenges and research priorities.
Next steps
- Visit ClinicalTrials.gov and search "1p36 deletion syndrome" to monitor for new observational studies.
- Connect with the 1p36 Deletion Support & Awareness foundation to stay updated on emerging research.
- Consult your medical geneticist about enrolling in natural history registries, which help researchers track the progression of 1p36 Deletion Syndrome.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult a qualified healthcare professional regarding any medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD): 1p36 Deletion Syndrome
- Orphanet: 1p36 deletion syndrome (ORPHA:96127)
- Online Mendelian Inheritance in Man (OMIM): 607872
- 1p36 Deletion Support & Awareness Foundation
